SELECT PUBLICATIONS

Arriagada R et al; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350(4):351-60. Abstract

Barlesi F et al. Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials. Proc ASCO 2005;Abstract 7213.

Bria E et al. Does adjuvant chemotherapy improve survival in non-small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit. Presentation. ASCO 2005;Abstract 7140.

Douillard J et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Proc ASCO 2005;Abstract 7013.

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract

Hotta K et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2004;22(19):3852-9. Abstract

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial E4599. Proc ASCO 2005;Abstract 4.